日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management

针对EGFR突变型非小细胞肺癌患者的个性化治疗:从早期到晚期疾病管理

Borgeaud, Maxime; Olivier, Timothée; Bar, Jair; Saw, Stephanie Pei Li; Parikh, Kaushal; Banna, Giuseppe Luigi; De Vito, Claudio; Feldman, Jill; Le, Xiuning; Addeo, Alfredo

Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back

非小细胞肺癌免疫治疗中检查点抑制剂的原发性和获得性耐药:从临床到实验室再到临床

Mariniello, Annapaola; Borgeaud, Maxime; Weiner, Marc; Frisone, Daniele; Kim, Floryane; Addeo, Alfredo

Estrogens determine the efficacy of cancer immunotherapy in obese males with melanoma.

雌激素决定了肥胖男性黑色素瘤患者接受癌症免疫疗法的疗效

Dupuychaffray Eloïse, Poinot Hélène, Vuilleumier Aurélie, Borgeaud Maxime, Alvarez Montserrat, Taskoparan Betül, Preynat-Seauve Olivier, Voegel Clarissa D, Marinari Eliana, Migliorini Denis, Dutoit Valérie, Bourquin Carole, Pommier Aurélien

Case Report: Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation: a case series and literature review

病例报告:曲美替尼治疗携带NF1突变的转移性肺腺癌患者:病例系列及文献综述

Kim, Floryane; Borgeaud, Maxime; De Vito, Claudio; Tsantoulis, Petros; Addeo, Alfredo

Rates of febrile neutropenia and its causes in the real world

现实世界中发热性中性粒细胞减少症的发生率及其病因

Borgeaud, Maxime; Perano, Simona; Addeo, Alfredo; Tsantoulis, Petros

Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer

在非小细胞肺癌的治疗中更早地引入免疫检查点抑制剂

Borgeaud, Maxime; Friedlaender, Alex; Addeo, Alfredo

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

非小细胞肺癌中的致癌驱动突变:过去、现在和未来

Chevallier, Mathieu; Borgeaud, Maxime; Addeo, Alfredo; Friedlaender, Alex